Biotechnology

Repair Biotechnologies Announces Appointment of Noted Cardiologists to Scientific Advisory Board

July 3, 2024 9:00 AM

SYRACUSE, NY / ACCESSWIRE / July 3, 2024 / Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, today announced the appointments of Ronald P. Karlsberg, MD, FACC, MSCCT, FAHA, FACP, and Daniel Karlsberg, MD, FACC, FSCCT to its Scientific Advisory Board (SAB). The SAB comprises experts in cardiology, biochemistry of...

Read more

GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson’s Formulation With Endopure Life Sciences

July 2, 2024 9:00 AM

GB Sciences' Licensing Deal with Endopure Life Sciences will also include Rights to Develop and Market GB Sciences' Cannabinoid-based Treatments for a Suite of Neurological Disorders LAS VEGAS, NV / ACCESSWIRE / July 2, 2024 / GB Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, has signed a letter of intent outlining terms for a licensing deal with Endopure Life Sciences, LLC, a company...

Read more

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

July 1, 2024 8:35 AM

Kintara Therapeutics, Inc. (Nasdaq:KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, and TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided an overview of Kintara's and TuHURA's recent corporate and clinical advancements and outlined upcoming expected near...

Read more

Biovica Signs New Agreement Supporting Pharma Development

June 28, 2024 2:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 28, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, a leader in blood-based cancer monitoring, has signed a Master Service Agreement and the initial Work Order with a US-based biopharmaceutical company specializing in breast cancer. The agreement enables Biovica to provide TKa testing services to support the development of new therapeutic treatments through pre-clinical and clinical...

Read more

Biovica International AB - Annual Report for the Financial Year 2023/2024 Published

June 28, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 28, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Annual report for the financial year 2023/2024 for Biovica International AB is published today on our website. See URL below. Contact Anders Rylander, CEO Phone: +46 76 666 16 47 E-mail: [email protected] Anders Morén, CFO Phone: +46 73 125 92 46 E-mail: [email protected] Biovica - Treatment decisions with greater...

Read more

Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting

June 27, 2024 12:45 PM

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below. Proxy Voting Results Ordinary Resolutions Votes for % of votes cast for Votes Against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes...

Read more

Form Bio and PacBio Announce Collaboration to Launch New Resources Set to Transform AAV Design and Analysis Best Practices

June 27, 2024 9:00 AM

Companies Form Expert Working Group to Introduce Essential Tools for AAV Development and Research Professionals SAN FRANCISCO / ACCESSWIRE / June 27, 2024 / Form Bio, the provider of advanced computational life sciences technology and PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a range of new initiatives aimed at advancing and unifying the AAV industry. The initiatives,...

Read more

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

June 27, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides takeaways from Geoff Birkett, the Company's Chief Commercial Officer, following his participation on the opening panel of the European Pharmaceutical Market Research...

Read more

Clarification of Notice to Extraordinary General Meeting

June 27, 2024 4:50 AM

UPPSALA, SE / ACCESSWIRE / June 27, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The purpose of the extra general meeting that Biovica has called for on July 15, 2024, is to decide on share-based incentive programs for employees and the board of Biovica International AB and subsidiaries. By doing so at an extraordinary general meeting, the company avoids trading that the incentive program generates during the subscription...

Read more

Notice of the Extra General Meeting in Biovica International AB

June 27, 2024 3:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 27, 2024 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Monday 15 July 2024, at 14:00 CET at Baker McKenzie's office at Vasagatan 7 in Stockholm. Right to attend the general meeting Shareholders wishing to attend the general meeting must: i. on the...

Read more

BioInvent Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 at PAGE 2024

June 26, 2024 4:20 AM

Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be held in Rome, Italy, June 26 to 28, 2024 LUND, SE / ACCESSWIRE / June 26, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company...

Read more

Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer

June 26, 2024 2:20 AM

LUND, SE / ACCESSWIRE / June 26, 2024 / Alligator Bioscience (STO:ATORX) Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously reported for FOLFIRINOX Further deepening of tumor shrinkage was evident with additional objective responses over long treatment duration Results demonstrate an unprecedented median Duration of Response of 12.6 months and confirm...

Read more

Alligator Bioscience Announces Financing of Up to SEK 80 Million Extending Cash Runway to Q1 2025

June 25, 2024 2:45 PM

The board of directors of Alligator Bioscience AB (publ) (STO:ATORX) ("Alligator" or the "Company") has today resolved on a directed issue of convertibles to Fenja Capital II A/S ("Fenja") raising gross proceeds of SEK 12 million (the "Convertibles"). Furthermore, the Company has also entered into an agreement with Fenja for a loan facility of up to SEK 68 million (the "Loan Facility" and together with the Convertibles, the "Financing"). The...

Read more

InDevR Launches 5’CapQ for Rapid Critical Quality Attribute Determination of mRNA-Based Vaccines

June 25, 2024 11:00 AM

New Kit Lets Vaccine Manufacturers Test 5′ Capping Efficiency at the Bench, With Answers in Less Than Two Hours BOULDER, CO / ACCESSWIRE / June 25, 2024 / InDevR Inc ., a leader in analytical solutions for vaccine in-process and quality control testing, is excited to announce the launch of 5'Cap Q for fast determination of 5' capping efficiency of mRNA. This ready-to-go, validated kit for the company's VaxArray Platform gives mRNA vaccine...

Read more

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

June 25, 2024 9:00 AM

IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Thursday, June 27, 2024 at 4:00 PM ET. As part of the event, Mr. Berman will discuss the Company's recently...

Read more

Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System

June 24, 2024 6:21 PM

SEATTLE, WA / ACCESSWIRE / June 24, 2024 / Product Creation Studio (PCS), a premier provider of engineering and design services, is excited to announce a new partnership with PatchClamp Medtech Inc. (PMI). This collaboration focuses on developing PatchClamp's novel dural repair graft placement system, designed to address the challenges of durotomy-perforations in the dura during cranial and spinal surgeries-which can lead to severe complications...

Read more

BioInvent Gains Patent for BI-1808 in China

June 24, 2024 8:30 AM

LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notice of allowance, informing the company that a patent application relating to the...

Read more

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

June 24, 2024 8:20 AM

This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridiprubart was selected following a competitive review process of multiple host-directed therapeutic candidates. TORONTO, ON / ACCESSWIRE / June 24, 2024 / Edesa...

Read more

Eyam Announces Nicholas Franco Appointment to Board of Advisors

June 24, 2024 7:00 AM

Eyam is pleased to announce the appointment of Nicholas Franco to its Board of Advisors. Mr. Franco brings a wealth of experience and strategic vision from his extensive career in the pharmaceutical industry. Mr. Franco has held key executive level leadership positions in several prominent organizations, including his most recent role as Executive Vice President and Chief Business Development Officer at Actelion, a Janssen Pharmaceutical...

Read more

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting

June 21, 2024 8:35 AM

enVVeno Medical Corporation (NASFAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that positive interim venous ulcer healing data showing significant clinical improvement from the SAVVE U.S. pivotal trial for the VenoValve will be presented today at the Society for Vascular Surgery 2024 Vascular Annual Meeting in Chicago. The data being presented includes...

Read more